Status:
COMPLETED
Study of Prone Accelerated Breast And Nodal IMRT
Lead Sponsor:
NYU Langone Health
Conditions:
Lymphedema
Eligibility:
FEMALE
36-90 years
Phase:
NA
Brief Summary
Following consent, patients will receive 15 fractions of radiotherapy to the affected breast and to Axillary level III and SCV (Supra-Clavicular) lymph nodes, defined by CT imaging obtained in a prone...
Detailed Description
A recent Cochrane Collaboration Intervention Review has addressed the effects of altered fractionation size on women with early breast cancer who have undergone breast conservation surgery. Analysis o...
Eligibility Criteria
Inclusion
- Pre- or post-menopausal women with stage II - III breast cancer (AJCC 2002)
- Biopsy-proven invasive breast cancer, excised with negative margins of at least 1 mm
- Status post segmental mastectomy or mastectomy and axillary node dissection with removal of at least 8 nodes
- One to 5 involved lymph nodes identified at axillary staging
- At least 2 weeks from last chemotherapy or before chemotherapy
- No more than sixty days from final surgery to simulation if no systemic therapy (includes chemotherapy and Hormonal therapy) is given
- Patient needs to be able to understand and demonstrate willingness to sign a written informed consent document
Exclusion
- Previous radiation therapy to the ipsilateral breast
- More than 5 involved nodes identified at axillary staging
- Current treatment for active connective tissue disorders, such as lupus or scleroderma
- Pregnant or lactating women
- Less than 35 years old
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 12 2021
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT02308488
Start Date
September 1 2009
End Date
October 12 2021
Last Update
April 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Laura and Issac Perlmutter Cancer Center
New York, New York, United States, 10016